The potential anti-arrhythmic effect of SGLT2 inhibitors
Cardiovascular Diabetology
JULY 14, 2024
Sodium-glucose cotransporter type 2 inhibitors (SGLT2i) were initially recommended as oral anti-diabetic drugs to treat type 2 diabetes (T2D), by inhibiting SGLT2 in proximal tubule and reduce renal reabsorpti.
Let's personalize your content